On ECHEMI
Home > Drugs > Lung cancer
Lung cancer
Lung cancer occurs in the bronchial mucosa or glands, also known as bronchial lung cancer. In the past 50 years, many countries have reported that the incidence of lung cancer has increased significantly. Among male cancer patients, lung cancer has ranked first, and the incidence rate in women has also increased rapidly, accounting for the second or third most common malignant tumors in women. The male-female incidence ratio is 3~5:1, and the age of onset is mostly between 60-79 years old. The cause of lung cancer is still not completely clear. A large amount of data shows that long-term heavy smoking is an important pathogenic factor of lung cancer. For those who smoke more than 40 cigarettes a day for many years, the incidence of squamous cell carcinoma and undifferentiated cancer of the lung is 4 to 10 times higher than that of non-smokers. The incidence of lung cancer in urban residents is higher than that in rural areas, which may be related to air pollution and carcinogens contained in smoke. Therefore, non-smoking should be advocated and urban environmental sanitation work should be strengthened.
Related Drugs
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Vinorelbine Tartrate for Injection
Indication: Non-small cell lung cancer, metastatic breast cancer and refractory lymphoma, ovarian cancer, head and neck tumors.
Manufacturer:

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Vinorelbine Tartrate for Injection
Indication: Non-small cell lung cancer, metastatic breast cancer and refractory lymphoma, ovarian cancer, head and neck tumors.
Manufacturer:

Shanxi PUDE Pharmaceutical Co., Ltd.

Vinorelbine Tartrate for Injection
Indication: This product is suitable for patients with non-small cell lung cancer and breast cancer.
Vinorelbine Tartrate for Injection
Indication: Non-small cell lung cancer, metastatic breast cancer and refractory lymphoma, ovarian cancer, head and neck tumors.
Manufacturer:

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Vinorelbine Tartrate for Injection
Indication: Non-small cell lung cancer, metastatic breast cancer and refractory lymphoma, ovarian cancer, head and neck tumors.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.

Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Hainan Zhuotai Pharmaceutical Co., Ltd.

Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Hainan New Way Pharmaceufical Co., Ltd.

Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:

Hubei Ouli Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.